Crowdfunding Platform - Capital Cell review

flag

Spain

icon

Equity crowdfunding

icon

Healthcare

EUR

Swedish French Dutch Spanish English

Funded in 2014

On the Capita cell, you can invest in shares of medical startups with x10+ return potential.

Capital Cell selects promoters through a multi-step screening focused on scientific, commercial, and legal quality. Promoters must submit detailed project, team, and financial information, which is reviewed by Capital Cell and its expert BioExpert Network for feasibility and investment merit. If approved, the promoter agrees on campaign terms and completes legal and financial due diligence. Before a public launch, a private pre-campaign must demonstrate traction, including a committed lead investor (around 15%), at least 20% of the target reserved, and interest from a minimum number of investors. Capital Cell may refuse publication if documentation, investor interest, or the promoter’s promotional capacity is insufficient.

Basic information

151 projects funded
144000000.0 EUR funded amount

License/regulation: CAPITAL CELL licensed under European Crowdfunding Service Providers (ECSP) regulation

For Investors

Limitations: In principle, any citizen or company of any country that is not on the list of tax havens of the Spanish government. However, in case of natural person it is required to have the NIE and in case of company, Spanish CIF.
Minium investment: 100 EUR

Useful Information

How does Capital Cell work?

Capital Cell operates as an Equity crowdfunding platform offering investors to invest in startups and early-stage companies through acquiring company shares. On the other hand offering companies am alternative fundraising tool to raise funds from a large pool of investors.

What investments does Capital Cell offer?

On Capital Cell  you can invest in  European startups from healthcare and biotech industries 

What is a risk when investing on Capital Cell ?

When investing on Capital Cell you invest in early-stage companies which makes it a high-risk investment since statistically 9 of 10 early-stage companies fail. You as an investor have to carefully evaluate such investments including product, product-market fit, company team and their ability to successfully develop a company, total addressable and reachable market and company growth potential, and other risks depending on business specifics.
 

Rating

This platform have no rating yet. Be the first to rate!

Capital Cell Reviews

Filter By Rating
  • Sort By